This prospective multicenter study evaluated separately the significance of maternal injection drug use (IDU) and human immunodeficiency virus type 1 (HIV-1) coinfection in vertical transmission of hepatitis C virus (HCV). In all, 1372 consecutive, unselected HCV antibody-positive mothers and their infants were studied. Maternal HIV-1 coinfection (crude odds ratios [OR], 1.41; 95% confidence interval [CI], 1.16-1.66; P ¼ .007) and IDU (OR, 1.58; 95% CI, 1.37-1.78; P , .00001) were linked to mother-to-child HCV transmission in unadjusted analysis when all anti-HCV-positive mothers were evaluated. When only HCV RNA-positive mothers were evaluated, maternal IDU, but not maternal HIV-1 coinfection, was significantly associated with motherto-child HCV transmission. Multivariable analysis confirmed the link between maternal IDU and HCV transmission (adjusted OR [AOR], 1.51; 95% CI, 1.19-1.92; P ¼ .0006), but no association was found with HIV-1 coinfection (AOR, 0.98; 95% CI, 0.73-1.33; P ¼ .93). IDU, but not HIV-1 coinfection, seems to be a preeminent risk factor for vertical HCV transmission.
Mother-to-child hepatitis C virus (HCV) transmission has been studied extensively, and correlates of transmission have been largely discussed. Previous reports showed transmission rates of 5.6%-12% [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Maternal viremia is universally considered to be a preeminent risk factor in vertical transmission and, even though intermittent viremia occurs, infection of infants born to mothers who were HCV RNA-negative during pregnancy has been reported anecdotally. No association has been found between mother-to-child HCV transmission and breast-feeding [2, 3, 8, 10, 12, 13] , and uncertain data have been reported on delivery [1, 3-6, 10, 13, 14] . Conversely, maternal human immunodeficiency virus type 1 (HIV-1) coinfection has been emphasized [3, [6] [7] [8] and is considered to be an important risk factor.
Studies indicate that 76%-100% of HCV-and HIV-1-coinfected women are also injection drug users (IDUs). We showed recently that such maternal drug use relates to the risk of mother-tochild transmission of HCV from HIV-1-negative mothers [10] . To evaluate separately the significance and interaction of the 2 risk factors, a large sample of mother-infant pairs is necessary. For this purpose, a multicenter prospective study was designed to evaluate by multivariable analysis the significance of risk factors thought to be correlated with mother-to-child HCV transmission, with particular emphasis on HIV-1 coinfection and IDU.
Patients and Methods
Data collection. Twenty-four medical departments throughout Italy participated in the study. The diagnosis of maternal HCV infection was based on the detection of anti-HCV in serum by secondgeneration ELISA and confirmed by Western blot assay. Blood samples were obtained from mothers during pregnancy and at delivery and from infants at birth or within 3 months and then >3 times during the subsequent 2-year follow-up period. Cord blood was never used for testing for HCV or HIV-1. Maternal HCV RNA was evaluated in the third term of pregnancy or at the time of delivery in anti-HCV-positive mothers. Maternal HIV-1 infection was diagnosed in the presence of anti-HIV-1 antibodies detected by ELISA and confirmed by Western blot. Children were considered to be HCV infected when HCV RNA was detected in peripheral blood by reverse-transcriptase (RT)-polymerase chain reaction (PCR) or when anti-HCV persisted beyond age 2 years. HIV-1 infection was diagnosed through detection of proviral DNA by PCR in >2 serum samples [15, 16] . Data regarding mother-infant pairs were collected through specific anonymous registration and follow-up forms. The registration form included specific questions concerning the infant's demographic data, gestational age, type of delivery, birth weight, type of feeding, maternal IDU (present or past), maternal HIV-1 coinfection, and maternal HCV RNA status. The follow-up forms included information on the child's HCV and HIV-1 infection status. Other data were not requested in the forms. History of IDU was carefully investigated by face-to-face interview with experienced doctors who used standardized questionnaires and by review of medical and drug addiction service records.
Definitions of preterm delivery (gestational age <36 weeks) and low birth weight (<2500 g) have been reported elsewhere [16] . In 32 anti-HCV-and HIV-1-positive mothers, elective cesarean sections were done to prevent HIV-1 transmission [17] . All other cesarean sections were done for obstetrical reasons independent of maternal HCV or HIV infection. Definitions of children ever breast-fed or exclusively formula-fed were as described elsewhere [18] . Each mother decided whether to breast-feed her baby, but HIV-1-infected mothers were advised not to breast-feed [18] .
Laboratory methods. HCV antibodies were evaluated by secondgeneration EIAs (Ortho Diagnostics) and confirmed by Western blotting (InnoLIA; Innogenetics). HCV RNA was determined by RT-PCR with nested primers derived from 5 0 , the noncoding region. Antibodies to HIV-1 were measured by ELISA and confirmed by Western blotting. HIV-1 proviral DNA was measured by nested PCR of 2 viral regions.
Study design. The study design included the following steps: all pregnant women observed in 24 referral centers from April 1993 through December 1996 were tested for HCV antibodies by EIA and by confirmatory tests. All anti-HCV-positive women were enrolled in the study. All infants born after enrollment of the mothers were screened for HCV RNA within 3 months after birth, and both anti-HCV and HCV RNA were evaluated during the subsequent 2-year follow-up. Twin pairs and siblings were excluded. Infants of HIV-1-seropositive women also were tested for HIV-1. Risk factors for HCV transmission (reported in registration and follow-up forms) were analyzed, including maternal HIV-1 coinfection, IDU, gestational age, birth weight, type of delivery, and type of feeding.
Statistical analysis. Differences in frequencies were evaluated by x 2 test. Differences in probabilities were tested by the MantelCox method [19] . Risk factors for mother-to-child transmission of HCV were analyzed in unadjusted analysis, and crude odds ratios (ORs) of maternal HIV-1 coinfection, maternal IDU, gestational age, birth weight, delivery type, and type of feeding were calculated. Subsequently, a multivariable analysis was done to clarify independent parameters associated with mother-to-child transmission of HCV, and adjusted ORs (AORs) were calculated. Two-tailed P values were taken into account; P , :05 was defined as significant. Data were processed with the SPSS X statistical package (SPSS).
Results
HCV antibodies were found in 1493 mothers: 121 (8.1%) mother-infant pairs dropped out, and 1372 completed the study. Table 1 shows the main epidemiologic and clinical features of the mothers and infants. History and clinical data did not differ between those who dropped out and those who completed the study. Of the children lost to follow-up, 51.2% were boys, 66.1% were born to viremic mothers, 11.6% had maternal HIV-1 coinfection, and 31.4% of their mothers were IDUs.
Cross-tabulation of HIV-1 status and history of IDU for HCV RNA-positive mothers is shown in table 2. Maternal HIV-1 positivity and history of IDU appear to be strictly related (P , 10 ÿ6 ). Of 1372 HCV-positive women, 98 of their infants acquired HCV infection (transmission rate, 7.1; 95% confidence interval [CI], 2.2%-7.2%). Of these 98 HCV-infected infants, 97 were born to HCV RNA-positive mothers (10.8% of 897 HCV RNA-positive mothers), and 1 was born to an HCV RNAnegative mother (0.3% of 387 HCV RNA-negative mothers). The HCV RNA status was missing for the remaining 88 women, none of whom gave birth to an infected infant. Of 194 HIV-1-coinfected mothers, 24 of their infants were HIV-1 infected (12.4%; 95% CI, 7.7%-17.1%) but none was HCV infected. Of the 461 IDU mothers, 23 were active users during pregnancy. Three of their infants (13.0%) were infected by HCV, and 1 had drug withdrawal symptoms. The rates of HCV transmission of mothers who were active drug users during pregnancy and of those who stopped injecting drugs before starting pregnancy was similar (13.0% vs. 11.4%; P ¼ :51). In the cohort of HIV-1-negative mothers (n ¼ 1178), 33 (10.8%) of 305 infants born to IDU mothers were infected by HCV, as were 42 (4.8%) of 873 infants born to non-IDU mothers (P ¼ :00022). For the IDU mothers (n ¼ 461), there were no differences in the rates of HCV transmission between HIV-1-positive and HIV-1-negative mothers (20 of 156 infected infants vs. 33 of 305, respectively; P ¼ :52). Table 3 shows the results of univariate analysis for all HCVpositive mothers. HCV transmission rates were higher in HIV-1-positive than in HIV-1-negative mothers, and the OR was significantly increased. Transmission was also significantly higher in mothers with a history of IDU. No other variable analyzed was significantly associated with mother-to-child HCV transmission. The frequency of vaginal deliveries was similar (P ¼ The variables that showed significance in univariate analysis and those largely discussed in the literature were included in the multivariable analysis. Results are reported in table 4. Maternal IDU but not HIV-1 coinfection was significantly associated with mother-to-child HCV transmission.
Because all but 1 infected infants were born to HCV RNApositive mothers, the most largely discussed risk factors (IDU, maternal HIV-1 coinfection, type of delivery, and type of feeding) were evaluated in the subset of viremic mothers. The data are reported in table 5. Maternal IDU, but not maternal HIV-1 coinfection, was significantly associated with mother-to-child HCV transmission. Multivariable analysis of the subset of HCV viremic mothers showed that maternal IDU (AOR, 1.51; 95% CI, 1.19-1.92; P ¼ :0006) but not maternal HIV-1 coinfection (AOR, 0.98; 95% CI, 0.73-1.33; P ¼ :93) was significantly associated with mother-to-child HCV transmission.
Discussion
This study of mother-to-child HCV transmission had a large sample of mother-infant pairs available for statistical analysis and consistent numbers of HIV-1-coinfected and IDU mothers. Our data confirm that the transmission rate from HCV-positive mothers is low (7.1%); HCV transmission occurred almost exclusively from HCV RNA-positive mothers. The infection of 1 infant born to an HCV RNA-negative mother may be explained by intermittent maternal viremia, although a laboratory error can not be excluded. Virus load has an important role in HCV mother-to-child transmission, although median levels of HCV RNA in transmitting and nontransmitting mothers may overlap [1, 5, 7, 8, 10, 13] . The evaluation of maternal virus load was not planned in the present study because of the high cost of the test.
The large number of subjects enrolled yielded 98 motherinfant pairs in which infants were infected and 1274 pairs in which infants were not infected. Univariate analysis of risk factors for HCV transmission supported previous results of no significant role for putative risk factors, such as gestational age, birth weight, or breast-feeding [1, 3, 5, [10] [11] [12] [13] . The lower frequency of IDU mothers who breast-fed their infants would obviously go toward the null hypothesis if breast-feeding plays a role in HCV transmission. As for the controversial issue of vaginal versus cesarean section delivery, our data confirm the prior findings of no difference in transmission rates for infants delivered by either method [1, 3, 5, 10, 11, 14] . However, because of the low number of elective cesarean deliveries (per- formed only in HIV-1-positive mothers), we could not draw a definite conclusion. Recently, the protective efficacy of elective cesarean delivery has been reported [20] , but the low number of women studied requires confirmation in a larger sample. In previous reports that evaluated risk factors for motherto-child HCV transmission, most mothers coinfected with HIV-1 were also IDUs [6, 8] , so the relative risk associated with each condition could not be separated. Recently, the importance of maternal HIV-1 coinfection in vertical HCV transmission has been denied [13] .
The univariate analysis of all anti-HCV-positive mothers confirms findings in several prior studies that emphasized the enhanced risk of transmission by HIV-1-coinfected mothers [3, [6] [7] [8] and by IDU mothers [10] . In multivariable analysis of all the anti-HCV-positive mothers, only IDU (and not HIV-1 coinfection) was significantly associated with HCV transmission to infants. Similarly, when only HCV RNA-positive mothers were analyzed, only maternal IDU and not HIV-1 status of mothers was significantly associated with mother-to-child transmission of HCV. These results are strengthened by the analysis of all the HIV-1-negative mothers. Among HIV-1-negative mothers, the IDUs had significantly higher rates of HCV transmission to their infants than did the non-IDU mothers, which is similar to a report by Resti et al. [10] . In the analysis of the entire group of IDU mothers, no difference in HCV transmission rate was found between HIV-1-positive and HIV-1-negative mothers. As in previous reports, maternal HIV-1 positivity and IDU were highly correlated, and only the large number of mothers included in the present study allowed us to separate the risk associated with the 2 variables.
Estimates of IDU may be difficult because users often are reluctant to admit to injecting drugs; however, great attention was given in this study to the women's histories by using standardized questionnaires administered by experienced doctors and by cross-checking histories with medical records and records of drug use services. The percentage of IDUs among anti-HCVpositive pregnant women in this study is similar to that described by other authors in Italy [6, 13] . The percentage of HCV-positive mothers who are IDUs may be .75% when HCV-and HIV-1-coinfected women are studied [6] [7] [8] ; the percentage falls to 17%-44% in cohorts of HCV-positive, HIV-1-negative women [6, 8, 10] . In the present study, of the HCV-and HIV-1-coinfected mothers, 81% were IDUs, compared with 27% of the HIV-1-negative mothers. Why IDU may be a risk factor in vertical transmission of HCV is not clear, but explanations may include placental damage, which might favor fetal infection by HCV [21] . Our findings confirm that IDUs are at higher risk of HCV transmission, independently of active drug use during pregnancy [5] . Therefore, other mechanisms should be considered.
We demonstrated recently that vertical transmission of HCV is related to maternal peripheral blood mononuclear cell (PBMC) infection. Only in the presence of maternal PBMC that harbor the virus does HCV infection of the newborn occur [22] . Moreover, preliminary results by our group suggest that the frequency of PBMC infection by HCV is higher in IDU mothers than in mothers with no known risk factor.
PBMC infection in IDUs occurs more than twice as often as in non-IDU mothers. As a consequence, the risk of vertical transmission of HCV might be related to maternal PBMC infection, which is more frequent in IDU than in non-IDU women. The mechanisms favoring HCV entry in PBMC and the reasons why PBMC infection is more frequent in IDUs remains to be clarified. We suggest that viral factors linked to drug abuse may be implicated: HCV exhibits an enormous genomic diversity, and many different variants may be found in a single HCV carrier [23] . Repeated superinfections with different HCV variants are probably common in IDUs who share equipment with injecting partners. It has been hypothesized that different variants may have tropism for different cells [24] . It is possible that some variants may have selective advantages in the infection of offspring [25] . This hypothesis is supported by the observation that infants born to mothers with multiple HCV variants are usually infected by only 1 or few of them [25, 26] . Additional support comes from studies of mother-to-child HIV-1 transmission, which suggest that multiple superinfections by different HIV-1 variants favor the transmission of infection from mother to child [27] .
Some modes of maternal infection may be associated with higher levels of HCV viremia than others. High serum virus load in mothers is a risk factor for vertical transmission [6] [7] [8] [9] [10] [11] . Data regarding HCV load were not an aim of this study and were not available for all the mothers studied. However, higher virus load might be found both in maternal HIV-1 coinfection and in drug addiction, conditions associated with immune suppression [28, 29] . In previous studies, HCV load appeared to be greater in HIV-1-infected persons [29] as HIV-1 disease progressed and CD4 cell counts declined [7, 29] . Since virus load data were not available for all the patients evaluated in the present study, we cannot rule out that the low rate of HCV transmission from HIV-1-infected women may be due to a lower HCV load in the HIV-coinfected women. However, this hypothesis is unlikely, because all women in this large study were unselected and consecutive.
In conclusion, our results show that IDU, not coinfection with HIV-1, is a significant risk factor for mother-to-child HCV transmission. Further studies could explore other variables in IDU mothers, such as duration of drug abuse, frequency of drug use, duration of time since stopping IDU, or the immune function during pregnancy in active or past drug-addicted women. Regarding the last issue, even if the sample is limited in the present study, no difference in the rate of HCV transmission was found between mothers who used drugs during pregnancy and those who had stopped injecting before becoming pregnant. At present, all anti-HCV-positive women with a history of past or active drug addiction should be advised that, independently of HIV-1 coinfection, they are at higher risk of infecting their offspring.
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